Navigation Links
Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market

Company seeks partner to commercialize the technology

TORONTO, July 9 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) announced today that it has filed key patent applications based on its novel semen sexing discoveries and that it will now embark on the path to commercialization of this exciting technology.

Microbix' recent discoveries should provide a more cost-effective platform for semen sexing and significantly improve yields and quality of the sperm produced compared to the current commercial sexing technology.

Both are critical market factors that Microbix believes will allow the company to effectively penetrate and even expand the $3 billion Artificial Insemination (AI) market.

Semen sexing is instrumental to the dairy industry due to the growing international demand for female offspring and the negligible value of dairy bull calves.

"This market is attractive for its size and the absence of regulatory barriers, and importantly, our technology offers a predictable pathway through development to market," said William J. Gastle, C.E.O.

"Now that the intellectual property has been secured, we are focused on finding a strategic partner(s) to help realize Microbix' Semen Sexing Technology's (SST) significant commercial potential and we invite expressions of interest," said Mr. Gastle.

Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Mississauga.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to develop and commercialize SST; non-adoption of SST. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. Arrow International Files and Mails Definitive Proxy Materials
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Post Your Comments:
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... , Oct.12, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental ... which had been filed against the Company has been ... Petit , Chairman and CEO, stated, "As we suspected, ...
(Date:10/12/2015)... 2015 cell surface marker detection market ... according to a new report by Grand View Research, Inc. ... incidence of oncology diseases and other cell-associated disorders. --> ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ...
(Date:10/12/2015)... Oct. 12, 2015  Patara Pharma, a clinical-stage ... inflammatory diseases and conditions, today announced the closing ... financing. Concurrent with the close of its sale ... Loan and Security Agreement with Silicon Valley Bank ... million. Patara will use the funds from the ...
Breaking Biology Technology:
(Date:9/10/2015)... This report provides detailed descriptions of the ... emerging sensor types that will dominate in the future. ... the wearable technology hype curve in the last five ... feature with all of them is the prominence of ... useful functions. Sensors collect data about the physical and ...
(Date:9/10/2015)... Report Details The global wearable ... previous expectations of revenues, consumer adoption and even technological ... which wearables begin to achieve that mass market acceptance ... reasons is the entrance of Apple to the SmartWatches ... but the overall size of the wearable technology market. ...
(Date:9/10/2015)... Conn. , Sept. 10, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... based ecommerce site, Touch of Modern, will feature ... Wednesday, September 16 th . ... wide range of designer lifestyle products to its 7.2 ...
Breaking Biology News(10 mins):